Is Myriad Genetics Stock a Good Investment?
Myriad Genetics Investment Advice | MYGN |
- Examine Myriad Genetics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Myriad Genetics' leadership team and their track record. Good management can help Myriad Genetics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Myriad Genetics' business and its evolving consumer preferences.
- Compare Myriad Genetics' performance and market position to its competitors. Analyze how Myriad Genetics is positioned in terms of product offerings, innovation, and market share.
- Check if Myriad Genetics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Myriad Genetics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Myriad Genetics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Myriad Genetics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Somewhat reliable | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Myriad Genetics Stock
Researching Myriad Genetics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 98.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.88. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Myriad Genetics has Price/Earnings To Growth (PEG) ratio of 1.4. The entity recorded a loss per share of 1.28. The firm had not issued any dividends in recent years. Myriad Genetics had 2:1 split on the 26th of March 2009.
To determine if Myriad Genetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Myriad Genetics' research are outlined below:
| Myriad Genetics generated a negative expected return over the last 90 days | |
| Myriad Genetics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 753.2 M. Net Loss for the year was (263.3 M) with profit before overhead, payroll, taxes, and interest of 476.4 M. | |
| Myriad Genetics currently holds about 205.1 M in cash with (110.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.54. | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from forbes.com: The Myriad Leader Shifting The Way We Think About Leadership |
Myriad Genetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Myriad Genetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Myriad Genetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Myriad Genetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Myriad Genetics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2002-05-07 | 2002-03-31 | -0.08 | -0.07 | 0.01 | 12 | ||
2002-02-05 | 2001-12-31 | -0.06 | -0.05 | 0.01 | 16 | ||
2001-08-21 | 2001-06-30 | -0.05 | -0.04 | 0.01 | 20 | ||
2001-05-09 | 2001-03-31 | -0.05 | -0.04 | 0.01 | 20 | ||
2000-11-02 | 2000-09-30 | -0.05 | -0.04 | 0.01 | 20 | ||
2000-05-09 | 2000-03-31 | -0.06 | -0.05 | 0.01 | 16 | ||
2000-02-10 | 1999-12-31 | -0.06 | -0.05 | 0.01 | 16 | ||
1999-08-31 | 1999-06-30 | -0.05 | -0.06 | -0.01 | 20 |
Know Myriad Genetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Myriad Genetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Myriad Genetics backward and forwards among themselves. Myriad Genetics' institutional investor refers to the entity that pools money to purchase Myriad Genetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 2.4 M | Sei Investments Co | 2024-06-30 | 2.4 M | Geode Capital Management, Llc | 2024-06-30 | 2.1 M | Citadel Advisors Llc | 2024-06-30 | 1.8 M | Nuveen Asset Management, Llc | 2024-06-30 | 1.4 M | Glenview Capital Management Llc | 2024-09-30 | 1.3 M | D. E. Shaw & Co Lp | 2024-06-30 | 1.1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.1 M | Northern Trust Corp | 2024-09-30 | 967.2 K | Blackrock Inc | 2024-06-30 | 15.2 M | Vanguard Group Inc | 2024-09-30 | 10.3 M |
Myriad Genetics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.38 B.Market Cap |
|
Myriad Genetics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.19) | (0.18) | |
| Return On Capital Employed | (0.10) | (0.10) | |
| Return On Assets | (0.08) | (0.08) | |
| Return On Equity | (0.13) | (0.11) |
Determining Myriad Genetics' profitability involves analyzing its financial statements and using various financial metrics to determine if Myriad Genetics is a good buy. For example, gross profit margin measures Myriad Genetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Myriad Genetics' profitability and make more informed investment decisions.
Myriad Genetics' Earnings Breakdown by Geography
Evaluate Myriad Genetics' management efficiency
Myriad Genetics has return on total asset (ROA) of (0.0535) % which means that it has lost $0.0535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.164) %, meaning that it created substantial loss on money invested by shareholders. Myriad Genetics' management efficiency ratios could be used to measure how well Myriad Genetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 22nd of November 2024, Return On Tangible Assets is likely to grow to -0.18. In addition to that, Return On Capital Employed is likely to grow to -0.1. At this time, Myriad Genetics' Non Current Assets Total are very stable compared to the past year. As of the 22nd of November 2024, Non Currrent Assets Other is likely to grow to about 16.2 M, while Total Assets are likely to drop about 670.7 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 9.89 | 5.38 | |
| Tangible Book Value Per Share | 2.45 | 2.54 | |
| Enterprise Value Over EBITDA | (16.69) | (15.85) | |
| Price Book Value Ratio | 1.52 | 1.44 | |
| Enterprise Value Multiple | (16.69) | (15.85) | |
| Price Fair Value | 1.52 | 1.44 | |
| Enterprise Value | 1.1 B | 790.3 M |
At Myriad Genetics, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Beta 1.937 |
Basic technical analysis of Myriad Stock
As of the 22nd of November, Myriad Genetics secures the Standard Deviation of 3.43, risk adjusted performance of (0.18), and Mean Deviation of 2.14. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Myriad Genetics, as well as the relationship between them.Myriad Genetics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Myriad Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Myriad Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Myriad Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Myriad Genetics' Outstanding Corporate Bonds
Myriad Genetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Myriad Genetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Myriad bonds can be classified according to their maturity, which is the date when Myriad Genetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MYLAN N V Corp BondUS62854AAP93 | View | |
| MYLAN N V Corp BondUS62854AAN46 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MYLAN INC 54 Corp BondUS628530BC02 | View | |
| MYLAN INC 455 Corp BondUS628530BK28 | View | |
| MYLAN INC Corp BondUS628530BJ54 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Understand Myriad Genetics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Myriad Genetics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.18) | |||
| Market Risk Adjusted Performance | (1.56) | |||
| Mean Deviation | 2.14 | |||
| Coefficient Of Variation | (396.67) | |||
| Standard Deviation | 3.43 | |||
| Variance | 11.76 | |||
| Information Ratio | (0.28) | |||
| Jensen Alpha | (0.93) | |||
| Total Risk Alpha | (1.32) | |||
| Treynor Ratio | (1.57) | |||
| Maximum Drawdown | 27.15 | |||
| Value At Risk | (6.12) | |||
| Potential Upside | 4.24 | |||
| Skewness | (1.68) | |||
| Kurtosis | 9.72 |
| Risk Adjusted Performance | (0.18) | |||
| Market Risk Adjusted Performance | (1.56) | |||
| Mean Deviation | 2.14 | |||
| Coefficient Of Variation | (396.67) | |||
| Standard Deviation | 3.43 | |||
| Variance | 11.76 | |||
| Information Ratio | (0.28) | |||
| Jensen Alpha | (0.93) | |||
| Total Risk Alpha | (1.32) | |||
| Treynor Ratio | (1.57) | |||
| Maximum Drawdown | 27.15 | |||
| Value At Risk | (6.12) | |||
| Potential Upside | 4.24 | |||
| Skewness | (1.68) | |||
| Kurtosis | 9.72 |
Consider Myriad Genetics' intraday indicators
Myriad Genetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Myriad Genetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Myriad Genetics Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 11th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Myriad Stock media impact
Far too much social signal, news, headlines, and media speculation about Myriad Genetics that are available to investors today. That information is available publicly through Myriad media outlets and privately through word of mouth or via Myriad internal channels. However, regardless of the origin, that massive amount of Myriad data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Myriad Genetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Myriad Genetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Myriad Genetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Myriad Genetics alpha.
Myriad Genetics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Myriad Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Myriad Genetics Historical Investor Sentiment
Investor biases related to Myriad Genetics' public news can be used to forecast risks associated with an investment in Myriad. The trend in average sentiment can be used to explain how an investor holding Myriad can time the market purely based on public headlines and social activities around Myriad Genetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Myriad Genetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Myriad Genetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Myriad Genetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Myriad Genetics.
Myriad Genetics Corporate Management
| Justin Hunter | Interim Secretary | Profile | |
| Nicole Lambert | Chief Officer | Profile | |
| Jennifer Fox | Chief Officer | Profile | |
| Clivetty Martinez | Chief Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.28) | Revenue Per Share 9.205 | Quarterly Revenue Growth 0.112 | Return On Assets (0.05) | Return On Equity (0.16) |
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Myriad Genetics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.